An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX: RCE) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens.
RECCE® 327 and RECCE® 529 have been designed with a unique mechanism of action, with the goal of re-empowering physicians in their potential of an effective treatm...
An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX: RCE) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens.
RECCE® 327 and RECCE® 529 have been designed with a unique mechanism of action, with the goal of re-empowering physicians in their potential of an effective treatment that may be used repeatedly against a broad range of bacteria and viruses. RECCE® 529 is a new synthetic polymer formulation with indication against viruses.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.